| Description | Ctsl Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ctsl gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control. Components Ctsl siRNA-1: 5 nmol (HPLC) Ctsl siRNA-2: 5 nmol (HPLC) Ctsl siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 Ctsl Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ctsl gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control. Components Ctsl siRNA-1: 5 nmol (HPLC) Ctsl siRNA-2: 5 nmol (HPLC) Ctsl siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Biochemical Test:SDS-PAGE (purity> 80%); Western blot with patient sample.Calculated Isoelectric Point:pH 8.83 | Seals and prevents freezing of stopcocks and ground-glass joints in high-vacuum systems at pressures less than 10-6 mm Hg. Heat stable (?40 to 260 °C), low vapor pressure, and chemically resistant. Colorless. 5.3 oz. tube | Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases... Read More |